SCHEMBL19639748

SCHEMBL19639748

CCC(=O)N(C)N(C(=O)OCc1ccccc1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 3/20 0.42
HPGD P15428 2/20 0.41
HTT P42858 1/20 0.41
PRKCA P17252 1/20 0.41
PRKCD Q05655 1/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 1/20 0.41
TBXA2R P21731 1/20 0.41
PTGIR P43119 1/20 0.41
PTGDR Q13258 1/20 0.41
CACNA1B Q00975 1/20 0.40
MAPT P10636 1/20 0.40
POLQ O75417 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19639758 0.79 ALOX15 (0.44) HPGDHTTALDH1A1CYP3A4CYP2C9
SCHEMBL19639772 0.78 KMT2A (0.46) PTGDR2HPGDHTTPRKCAPRKCD
SCHEMBL19688780 0.76 ALOX15 (0.42) HPGDHTTALDH1A1CYP3A4CYP2C9
SCHEMBL2095059 0.73 HPGD (0.50) HPGDHTTALDH1A1CYP3A4PTGIR
SCHEMBL9357893 0.72 LMNA (0.57) HPGDHTTALDH1A1MAPTPOLQ
SCHEMBL25177922 0.71 ITGB3 (0.49) PTGDR2PRKCAPRKCDALDH1A1KDM4E
SCHEMBL6647004 0.70 PRKCA (0.62) HTTPRKCAPRKCDALDH1A1MAPT
SCHEMBL5133571 0.70 HDAC1 (0.47) PTGDR2HPGDHTTALDH1A1CYP3A4
SCHEMBL20830725 0.69 LMNA (0.66) HPGDPRKCAPRKCDALDH1A1KDM4E
SCHEMBL19639789 0.69 HDAC1 (0.47) PTGDR2HPGDHTTALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464269-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A HNE RELATED DISEASE CHIESI FARM SPA (IT) 2020-04-01 EP disclosed
EP-3464269-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED Chiesi Farmaceutici S.p.A. (IT) 2019-04-10 EP disclosed
WO-2017207433-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED CHIESI FARMACEUTICI S.P.A. (IT) 2018-03-01 WO disclosed
WO-2017207433-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED CHIESI FARMACEUTICI S.P.A. (IT) 2018-03-01 WO disclosed
US-9862706-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-09 US disclosed
US-9862706-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-09 US disclosed
WO-2017207433-A1 HETETOCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED CHIESI FARMACEUTICI S.P.A. (IT) 2017-12-07 WO disclosed
WO-2017207433-A1 HETETOCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED CHIESI FARMACEUTICI S.P.A. (IT) 2017-12-07 WO disclosed
US-20170342056-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed
US-20170342056-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed
US-20170342056-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342056-A1 NOVEL COMPOUNDS SERPINB1, ELANE, MPO PTGDR2 1740/4885HPGD 26/4885HTT 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.